Skip to main content

Animations

MJFF Publications

7281 - 7290 of 9156 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2021
  • 2022
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Early Parkinson’s Disease Phenotypes Tailored by Personality, Behavior, and Motor Symptoms
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3233/jpd-213070
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Replication of a Novel Parkinson's Locus in a European Ancestry Population
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28546
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28548
    Citation Count: 49
  • Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease
    2022
    Summary Details
    RESTRICTED
    Title: Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28936
    Citation Count: 2
  • Parkinson's Kinesia Paradoxa Is Not a Paradox
    2021
    Summary Details
    OPEN
    Title: Parkinson's Kinesia Paradoxa Is Not a Paradox
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28550
    Citation Count: 34
  • Summary Details
    OPEN
    Title: Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28569
    Citation Count: 25
  • Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population‐Based CLSA
    2021
    Summary Details
    RESTRICTED
    Title: Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population‐Based CLSA
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28571
    Citation Count: 6
  • Reply to: “A New Approach to the Development of Disease‐Modifying Therapies for PD”
    2021
    Summary Details
    RESTRICTED
    Title: Reply to: “A New Approach to the Development of Disease‐Modifying Therapies for PD”
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28588
    Citation Count: 0
  • A New Approach to the Development of Disease‐Modifying Therapies for PD
    2021
    Summary Details
    RESTRICTED
    Title: A New Approach to the Development of Disease‐Modifying Therapies for PD
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28589
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28602
    Citation Count: 30
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.